| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 75.68% | Benchmark | → $39 | Reiterates | Buy → Buy |
| 08/07/2023 | 44.14% | Credit Suisse | $29 → $32 | Maintains | Neutral |
| 07/20/2023 | 71.17% | RBC Capital | → $38 | Reiterates | Outperform → Outperform |
| 05/08/2023 | 71.17% | RBC Capital | $32 → $38 | Maintains | Outperform |
| 05/08/2023 | 30.63% | Credit Suisse | → $29 | Reiterates | → Neutral |
| 02/27/2023 | 75.68% | Benchmark | → $39 | Reiterates | → Buy |
| 02/27/2023 | 30.63% | Credit Suisse | $24 → $29 | Maintains | Neutral |
| 11/07/2022 | 44.14% | RBC Capital | $36 → $32 | Maintains | Outperform |
| 05/17/2022 | 21.62% | Credit Suisse | $28 → $27 | Maintains | Neutral |
| 05/10/2022 | 62.16% | RBC Capital | $42 → $36 | Maintains | Outperform |
| 03/16/2022 | 26.13% | Credit Suisse | $37 → $28 | Maintains | Neutral |
| 03/07/2022 | 89.19% | RBC Capital | $47 → $42 | Maintains | Outperform |
| 01/18/2022 | 57.66% | B of A Securities | $40 → $35 | Maintains | Buy |
| 01/18/2022 | 111.71% | RBC Capital | $50 → $47 | Maintains | Outperform |
| 08/10/2021 | 75.68% | Credit Suisse | $37 → $39 | Maintains | Neutral |
| 05/10/2021 | 107.21% | Deutsche Bank | $42 → $46 | Maintains | Buy |
| 03/01/2021 | 53.15% | Credit Suisse | $32 → $34 | Maintains | Neutral |
| 01/05/2021 | 21.62% | Credit Suisse | $22 → $27 | Maintains | Neutral |
| 11/02/2020 | -0.9% | Credit Suisse | $19 → $22 | Maintains | Neutral |
| 08/04/2020 | 17.12% | Deutsche Bank | $24 → $26 | Maintains | Buy |
| 08/03/2020 | -14.41% | Credit Suisse | $18 → $19 | Maintains | Neutral |
| 06/16/2020 | -32.43% | B of A Securities | $18 → $15 | Downgrades | Neutral → Underperform |
| 05/04/2020 | -18.92% | Credit Suisse | $23 → $18 | Maintains | Neutral |
| 04/24/2020 | 8.11% | Deutsche Bank | $33 → $24 | Maintains | Buy |
| 04/03/2020 | 3.6% | Credit Suisse | $29 → $23 | Maintains | Neutral |
| 03/24/2020 | 12.61% | Benchmark | $33 → $25 | Reiterates | → Buy |
| 02/24/2020 | 48.65% | Deutsche Bank | $22 → $33 | Maintains | Buy |
| 11/04/2019 | 3.6% | Benchmark | $21 → $23 | Maintains | Buy |
| 09/17/2019 | -0.9% | Deutsche Bank | → $22 | Initiates Coverage On | → Buy |
| 05/17/2019 | -18.92% | JMP Securities | → $18 | Upgrades | Market Perform → Market Outperform |
| 01/07/2019 | -27.93% | Credit Suisse | $21 → $16 | Maintains | Neutral |
| 12/14/2018 | -9.91% | Barclays | → $20 | Initiates Coverage On | → Equal-Weight |
What is the target price for Select Medical Hldgs (SEM)?
The latest price target for Select Medical Hldgs (NYSE: SEM) was reported by Benchmark on November 8, 2023. The analyst firm set a price target for $39.00 expecting SEM to rise to within 12 months (a possible 75.68% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Select Medical Hldgs (SEM)?
The latest analyst rating for Select Medical Hldgs (NYSE: SEM) was provided by Benchmark, and Select Medical Hldgs reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Select Medical Hldgs (SEM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Select Medical Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Select Medical Hldgs was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
Is the Analyst Rating Select Medical Hldgs (SEM) correct?
While ratings are subjective and will change, the latest Select Medical Hldgs (SEM) rating was a reiterated with a price target of $0.00 to $39.00. The current price Select Medical Hldgs (SEM) is trading at is $22.20, which is within the analyst's predicted range.